fashion -WSS

fashion

author：fashion 2025-10-01 22:58:26 - browse：5

MODERNA - Norwood facility — Alex Hogan/STAT

Moderna announced Monday that, in a Phase 3 clinical trial, its combination Covid-19 and influenza vaccine generated stronger immune responses in older adults than individual vaccines that target those viruses.

The findings, disclosed in a press release, suggest the company may be on track to bring a combination flu and Covid vaccine to the market, potentially as early as autumn 2025.

“We’re excited to move forward in our discussions with regulators, and hopefully continue to help address respiratory viruses globally,” Moderna President Stephen Hoge told STAT in an interview in which he acknowledged that the fall 2025 vaccine rollout is a target the company would like to hit.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： Study: Spinal cord stimulation helps patients with paralysis walk again

leisure time

WSS

Roche drug slashes death risk in early

Harvard's Jason Buenrostro wins MacArthur grant for genetics work

Questions loom on AstraZeneca cancer drug as safety concerns ebb

Is there really a nursing shortage in the U.S.?

STAT Summit: Ending the crisis of Black deaths in the U.S.

STAT Summit: How researchers deal with rejection

focus

fashion

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

Continuity nursing helped my family in our darkest PICU moments

Smaller biotechs seek to piggyback on weight loss drug boom

After affirmative action ruling, medical educators look to 'holistic review'

Readout LOUD podcast: Live from the 2023 STAT Summit

As demand for Covid shots wanes, Moderna seeks its next success

Smaller biotechs seek to piggyback on weight loss drug boom

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Health officials lay out plans to cope with respiratory virus season

Moonlake's readout produced a cash windfall. Risks remain

Merck, Daiichi strike cancer drug pact worth up to $22 billion

hotspot

Can U.S. cancer drug shortages be fixed?

Wegovy improves function in certain heart failure patients

Vivek Ramaswamy made waves in the debate, much as in biotech

Roche drug slashes death risk in early

The future of Biogen: Pragmatism, ‘moonshots,’ and no Twinkies

Intellia plays down concerns on accidental germline transmission

focus

leisure time

explore

hotspot